Masataka Oitate - Concepedia

Author

Masataka Oitate

Daiichi-Sankyo (Japan)ORCID

Also Known As

Masataka Oitate

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Daiichi-Sankyo (Japan)

About

Masataka Oitate is an author at Daiichi-Sankyo (Japan) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	248
2	Natural Sciences	1	1	50
3	Biomolecular Engineering	1	1	50
4	Cell Biology	1	1	29
5	Cellular Physiology	1	1	29

Masataka Oitate

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara, Clinical Cancer Research	2016	1K
Bystander killing effect of <scp>DS</scp>‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity Yusuke Ogitani, Katsunobu Hagihara, Masataka Oitate, Cancer Science	2016	660
Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys Yoko Nagai, Masataka Oitate, Hideyuki Shiozawa, Xenobiotica Drug TargetingPreclinical Drug EvaluationCynomolgus MonkeysMedicineAntibody-drug Conjugate	2018	94
Prediction of Human Pharmacokinetics of Therapeutic Monoclonal Antibodies from Simple Allometry of Monkey Data Masataka Oitate, Noriko Masubuchi, Takashi Ito, Drug Metabolism and Pharmacokinetics	2011	78
CS-8958, a Prodrug of the Novel Neuraminidase Inhibitor R-125489, Demonstrates a Favorable Long-Retention Profile in the Mouse Respiratory Tract Kumiko Koyama, Makoto Takahashi, Masataka Oitate, Antimicrobial Agents and Chemotherapy MedicineImmunologyRadioactivity ConcentrationsActive Form R-125489Virology	2009	75
Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice Hiromi Okamoto, Masataka Oitate, Katsunobu Hagihara, Xenobiotica	2020	75
Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology Yusuke Ogitani, Yuki Abe, Takuma Iguchi, Bioorganic & Medicinal Chemistry Letters Wide ApplicationMedicinal ChemistryDrug TargetingPolymer-drug ConjugateMedicine	2016	50
Prediction of Human Plasma Concentration-time Profiles of Monoclonal Antibodies from Monkey Data by a Species-invariant Time Method Masataka Oitate, Shintaro Nakayama, Takashi Ito, Drug Metabolism and Pharmacokinetics	2011	35
Transcellular transport of genistein, a soybean‐derived isoflavone, across human colon carcinoma cell line (Caco‐2) Masataka Oitate, Rie Nakaki, Noriko Koyabu, Biopharmaceutics & Drug Disposition Chemoprevention StrategyUptake ExperimentSoybean-derived IsoflavoneCellular PhysiologyTumor Biology	2001	29
COVALENT BINDING OF RADIOACTIVITY FROM [14C]ROFECOXIB, BUT NOT [14C]CELECOXIB OR [14C]CS-706, TO THE ARTERIAL ELASTIN OF RATS Masataka Oitate, Takashi Hirota, Kumiko Koyama, Drug Metabolism and Disposition	2006	27

Page 1